Michael Kuhns, an associate professor of immunobiology at the University of Arizona who was not affiliated with the ASU study, said that having a better handle on what kinds of autoantibodies exist in healthy people may help scientists evaluate "how robust (a particular autoantibody) might be as a biomarker, even a diagnostic.”